Navigation Links
Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome
Date:1/15/2014

ences.  Key hormones, including adiponectin and leptin, also showed changes characteristic of non-PWS obese patients, demonstrating that the drug was highly active in these patients and had a similar effect to that seen in non-PWS patients.

"These results are very exciting for the treatment of PWS, as most patients showed improvements in body weight, hunger-related behaviors, and body fat content, despite the increased food intake included in the trial design," explained Dr. Jennifer Miller, Associate Professor of Pediatric Endocrinology, University of Florida, and Principal Investigator for the study.  "PWS is a complex genetic disease that is difficult to treat and the results of this trial demonstrate that beloranib has a beneficial impact on this underserved patient population.  Notably, we were encouraged by reports of fullness, a first-time occurrence for PWS patients who otherwise lack the capacity to feel sated after meals."

"PWS patients remain severely impacted by their disease and are not treatable with other anti-obesity agents," added Janalee Heinemann, Director of Research & Medical Affairs for the Prader-Willi Syndrome Association (USA).  "PWS represents one of the most severe forms of genetic obesity and we welcome these results, which are a significant step towards finding a treatment for those suffering from this life threatening condition."

Beloranib, a novel obesity therapy that utilizes a unique mechanism of action, is being studied for its ability to reduce body weight and improve cardiometabolic risk factors in obese patients with and without PWS.  This study was a randomized, double-blind, placebo-controlled trial to evaluate the safety and tolerability of a dose range of beloranib administered as twice-weekly subcutaneous injections for four weeks.  The randomized treatment part of the study was follow
'/>"/>

SOURCE Zafgen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
2. Zafgen Secures $21 Million in Series D Financing
3. Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013
4. Zafgen Secures $45 Million in Series E Financing
5. Zafgen Appoints Chief Commercial Officer and New Member of Board of Directors
6. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
7. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
8. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
9. Misonix Announces New Distribution Agreement For Panama
10. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015 Electrophysiologist Kevin ... recently traveled to Boston, MA ... the 2015 Heart Rhythm Society conference. These scientific ... focus on the ideas, people and technology that ... is a hybrid, minimally invasive cardiac operation that ...
(Date:5/22/2015)... 22, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a ... and regeneration, today announced that J.J. Finkelstein , ... a corporate overview at two upcoming investor conferences. ... 4 th Annual Microcap Conference on Thursday May ... at 11:00 am EDT.  A webcast will be ...
(Date:5/22/2015)... May 22, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... peer-reviewed publication of the results of the Company,s ... preservative-free eye drops) for the treatment of dry ... (CAE ® ) model.  The exploratory study was ... were previously disseminated by the Company in a ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4
... 22, 2011 Terso Solutions, Inc. has expanded its ... new refrigerator that is well-suited for hospital and ... the new refrigerator makes better use of space, reduces ... products such as reagents, cardiovascular products, tissue samples, and ...
... U.S. Food and Drug Administration today announced that Terumo ... two of its officers, Mark A. Sutter, president and ... Quality Assurance and Operations, have signed a consent decree ... ) The consent decree, to be ...
Cached Medicine Technology:Terso Solutions Launches New RFID-Enabled Refrigerator for Hospital and Laboratory Inventory Management 2FDA: Michigan Heart-Lung Bypass Machine Manufacturer Enters Into Consent Decree 2FDA: Michigan Heart-Lung Bypass Machine Manufacturer Enters Into Consent Decree 3
(Date:5/25/2015)... New York, New York (PRWEB) May 25, 2015 ... ( http://www.consumerinjurylawyers.com/depuy-pinnacle/lawsuit ) continue to move forward in ... District Court, Northern District of Texas. According to ... have asked the Court to modify the Case ... Disclose Health Information. Among other things, the Motion ...
(Date:5/25/2015)... White Plains, NY (PRWEB) May 25, 2015 ... LEED AP, principal of PBDW Architects in New York City, ... which is part of the hospital’s ongoing Legacy Lobby Lecture ... campus in White Plains. White is the great grandson of ... firm responsible for the design of Burke’s campus 100 years ...
(Date:5/24/2015)... Dallas, TX (PRWEB) May 24, 2015 ... the Global and Chinese Enterokinase Industry, 2009-2019 Market Research ... as it is an exhaustive study on the present ... a special insight into the growing Chinese market of ... market and the overall status of the manufacturers in ...
(Date:5/24/2015)... ProPin is a set of self-animating ... Utilize ProPin to pin point locations on a map, to ... , ProPin allows users to choose from 30 simplistic presets with ... on-screen controls, video editors can easily manipulate ProPin presets as a ... with absolute ease. , Using ProPin is easy, simply drag a ...
(Date:5/23/2015)... City, FL (PRWEB) May 23, 2015 On ... to build a new playground for Branches Florida City exactly ... the former play space in 2010. , A large fire ... new playground on May 23, 2010 in the middle of ... watched. The fire was later declared arson even though it ...
Breaking Medicine News(10 mins):Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 2Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 3Health News:Burke Rehabilitation Hospital Welcomes Architect Samuel White, Descendant of McKim, Mead and White, for Legacy Lobby Lecture 2Health News:Burke Rehabilitation Hospital Welcomes Architect Samuel White, Descendant of McKim, Mead and White, for Legacy Lobby Lecture 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 4Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Five Years After Fire, Branches Rebuilds Playground 2
... The FDA approved Tibotec,Pharmaceutical,s novel non-nucleoside ... announced introductory pricing for,the eagerly anticipated new ... other recently introduced antiretrovirals., "The efficacy ... DUET,studies is impressive. INTELENCE is an important ...
... Protects Sensitive Customer Health Care ... Data on Laptops and ... a global,leader in enterprise data protection, today announced that Payformance,Health, ... Electronic Funds Transfer (EFT) and Electronic Remittance,Advice (ERA) services, has ...
... reveals Boomers feel young, but often ignore important, health issues; company ... ... ST. LOUIS, Jan. 31 Baby boomers are living,longer and leading ... it comes to long-term health. According to a,recent survey by Energizer Holdings, ...
... ... -- Revises 2008 EPS Guidance Primarily to Reflect the Sale of Medical ... Imaging, -- Reaffirms Expected Non-GAAP EPS CAGR of at ... Through 2010, Subject to Certain Assumptions, -- Completes Sale of Medical Imaging Business, Reports as Discontinued, ...
... PARK CITY, Utah, Jan. 31 Nutraceutical,International Corporation (Nasdaq: ... first quarter ended December 31, 2007. Net sales for ... $35.8 million for the,same quarter of fiscal 2007. For ... million, or $0.28 diluted earnings per share, compared to,net ...
... Canadian Regulatory Authorities Approve 3f(R) Aortic Bioprosthesis for Sale ... ... Company Updates Financial Outlook for 2008, MINNEAPOLIS, Jan. 31 ... products and services, today announced it has received a request,for additional information and ...
Cached Medicine News:Health News:Tibotec Pharmaceuticals a Respectful Partner to HIV Community in Pricing of Novel New HIV NNRTI, INTELENCE 2Health News:Health Care Solutions Provider Payformance Health Standardizes on PGP Encryption for Data Security 2Health News:Health Care Solutions Provider Payformance Health Standardizes on PGP Encryption for Data Security 3Health News:Health Care Solutions Provider Payformance Health Standardizes on PGP Encryption for Data Security 4Health News:Boomers: Feeling Young or Fooling Themselves? 2Health News:Boomers: Feeling Young or Fooling Themselves? 3Health News:Boomers: Feeling Young or Fooling Themselves? 4Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 2Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 3Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 4Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 5Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 6Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 7Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 8Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 9Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 10Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 11Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 12Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 13Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 14Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 15Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 16Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 17Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 18Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 19Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 20Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 21Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 22Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 23Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 24Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 25Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 26Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 27Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 28Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 29
Full Handle Laseredge Stab Blade Knife, 22.5 blade. Blade tip dimension: 10.7 mm x 1.8 mm x 4.2 mm....
18 gauge tapered fine tip. Lightweight design offers precise hemostasis. Pencil design minimizes tissue trauma and induced astigmatism. Knurled handle provides a sure grip and better manipulation....
Set consist of two 27 gauge, stainless steel probes with blunt tips. Probes are 11.5 cm (4.5 inches) long with 30.5 cm (12 inches) of flexible tubing (O.D. - 0.60 mm, I.D. - 0.30 mm) attached onto th...
Curved, soft flexible tip allows atraumatic entry through a retinal tear or hole for aspiration of subretinal fluids. 20 gauge x 25 mm cannula attached to 25 gauge x 6 mm tip with 13 mm flexible tubi...
Medicine Products: